Press Releases Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
3.64 ^USD	-1.36%		-5.45%	-36.47%

Apr. 05	Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	MT
Apr. 04	Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Caribou Biosciences to Participate in Upcoming Investor Conferences	May. 01	AQ
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	Apr. 24	AQ
Caribou Biosciences : CB-010 ANTLER Case Study iwCAR-T 2024	Apr. 23	PU
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	Apr. 15	AQ
Caribou Biosciences : CB-012 IND-enabling preclinical data AACR 2024	Apr. 09	PU
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus	Apr. 04	AQ
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 11	AQ
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting	Mar. 05	AQ
Caribou Biosciences to Participate in Upcoming Investor Conferences	Feb. 15	AQ
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024	Jan. 07	AQ
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024	Dec. 12	AQ
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 07	AQ
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board	Nov. 06	AQ
Caribou Biosciences : CB-010 ANTLER Case Study	Nov. 01	PU
Caribou Biosciences to Participate in Upcoming Investor Conferences	Nov. 01	AQ
Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia	23-10-18	AQ
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer	23-09-27	AQ
Caribou Biosciences to Participate in Upcoming Investor Conferences	23-08-29	AQ
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-08	AQ
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering	23-07-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Press Releases

Filters